SG Americas Securities
ELEV

SG Americas Securities’s Elevation Oncology ELEV Stock Holding History

SG Americas Securities’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,711
Closed -$4K – 3124
2025
Q1 		$4K Sell
16,711
-44,756
-73% -$25.6K ﹤0.01% 3427
2024
Q4 		$35K Buy
61,467
+15,560
+34% +$9.19K ﹤0.01% 2964
2024
Q3 		$28K Buy
+45,907
New +$68.1K ﹤0.01% 3328
2024
Q2 		– Sell
-12,244
Closed -$63K – 2967
2024
Q1 		$63K Buy
+12,244
New +$39.7K ﹤0.01% 2694

Other funds holding ELEV

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

SG Americas Securities's ELEV Position: Q2 2025 in Review

SG Americas Securities sold out of Elevation Oncology (ELEV) in Q2 2025, closing a stake of 16,711 shares — an estimated $4K sold.

SG Americas Securities first reported a position in ELEV in Q1 2024 and held it in 4 quarters. The position peaked at $63K in Q1 2024. 65 funds tracked by Wall St. Rank hold ELEV as of Q2 2025.

  • SG Americas Securities reported no remaining Elevation Oncology position as of Q2 2025 after selling out during the quarter.
  • SG Americas Securities sold 16,711 Elevation Oncology shares in Q2 2025, an estimated $4K.
  • SG Americas Securities first reported a position in Elevation Oncology in Q1 2024 and held it in 4 quarters.
  • SG Americas Securities's Elevation Oncology position peaked at $63K in Q1 2024.
  • 65 funds tracked by Wall St. Rank held Elevation Oncology as of Q2 2025.

Based on SG Americas Securities's 13F filing for Q2 2025, filed 8 Aug 2025.